[1] |
Monney L, Sabatos CA, Gaglia JL, et al. Th1⁃specific cell surface protein Tim⁃3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature, 2002, 415(6871): 536⁃541. DOI: 10.1038/415536a.
|
[2] |
Nakae S, Iikura M, Suto H, et al. TIM⁃1 and TIM⁃3 enhancement of Th2 cytokine production by mast cells[J]. Blood, 2007, 110(7): 2565⁃2568. DOI: 10.1182/blood⁃2006⁃11⁃058800.
|
[3] |
Cua DJ, Sherlock J, Chen Y, et al. Interleukin⁃23 rather than interleukin⁃12 is the critical cytokine for autoimmune inflammation of the brain[J]. Nature, 2003, 421 (6924): 744⁃748. DOI: 10.1038/nature01355.
|
[4] |
Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor Tim⁃3 expressed on innate immune cells[J]. Science, 2007, 318 (5853): 1141⁃1143. DOI: 10.1126/science.1148536/.
|
[5] |
Wang F, He W, Zhou H, et al. The Tim⁃3 ligand galectin⁃9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft[J]. Cell Immunol, 2007, 250 (1⁃2): 68⁃74. DOI: 10.1016/j.cellimm.2008.01.006.
|
[6] |
Zhu C, Anderson AC, Kuchroo VK. TIM⁃3 and its regulatory role in immune responses[J]. Curr Top Microbiol Immunol, 2011, 350: 1⁃15. DOI: 10.1007/82_2010_84.
|
[7] |
Norling LV, Perretti M, Cooper D. Endogenous galectins and the control of the host inflammatory response[J]. J Endocrinol, 2009, 201(2): 169⁃184. DOI: 10.1677/JOE⁃08⁃0512.
|
[8] |
Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim⁃3 and PD⁃1 is associated with tumor antigen⁃specific CD8+ T cell dysfunction in melanoma patients[J]. J Exp Med, 2010, 207 (10): 2175⁃2186. DOI: 10.1084/jem.20100637.
|
[9] |
Gao X, Zhu Y, Li G, et al. TIM⁃3 characterizes regulatory T cells in tumor tissues and is associated with lung cancerprogression[J/OL]. PLoS One, 2012, 7 (2): e30676[2015⁃02⁃18]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030676. DOI: 10.1371/journal.pone.0030676.
|
[10] |
Yang ZZ, Grote DM, Ziesmer SC, et al. IL⁃12 upregulates TIM⁃3 and induces T cell exhaustion in patients with follicular B cell non⁃Hodgkin lymphoma[J]. J Clin Invest, 2012, 122(4): 1271⁃1282. DOI: 10.1172/JCI59806.
|
[11] |
Ngiow SF, von Scheidt B, Akiba H, et al. Anti⁃TIM3 antibody promotes T cell IFN⁃γ⁃mediated antitumor immunity and suppresses establishedtumors[J]. Cancer Res, 2011, 71(10): 3540⁃3551. DOI: 10.1158/0008⁃5472.CAN⁃11⁃0096.
|
[12] |
Monney L, Sabatos CA, Gaglia JL, et al. Th1⁃specific cell surface protein Tim⁃3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature, 2002, 415(6871): 536⁃541. DOI: 10.1038/415536a.
|
[13] |
Sánchez⁃Fueyo A, Tian J, Picarella D, et al. Tim⁃3 inhibits T helper type 1⁃mediated auto⁃ and alloimmune responses and promotes immunological tolerance[J]. Nat Immunol, 2003, 4(11): 1093⁃1101. DOI: 10.1038/ni987.
|
[14] |
Geng H, Zhang GM, Li D, et al. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell⁃mediated immune response[J]. J Immunol, 2006, 176(3): 1411⁃1420. DOI: 10.4049/jimmunol.176. 3.1411.
|